Articles with "drug tolerant" as a keyword



Photo from wikipedia

Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells.

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of the American Chemical Society"

DOI: 10.1021/jacs.2c03973

Abstract: Persister cancer cells represent rare populations of cells resistant to therapy. Cancer cells can exploit epithelial-mesenchymal plasticity to adopt a drug-tolerant state that does not depend on genetic alterations. Small molecules that can interfere with… read more here.

Keywords: cancer; tolerant pancreatic; drug tolerant; cancer cells ... See more keywords
Photo from wikipedia

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells

Sign Up to like & get
recommendations!
Published in 2021 at "Nature Communications"

DOI: 10.1038/s41467-020-20717-9

Abstract: Drug tolerant/resistant leukemic stem cell (LSC) subpopulations may explain frequent relapses in acute myeloid leukemia (AML), suggesting that these relapse-initiating cells (RICs) persistent after chemotherapy represent bona fide targets to prevent drug resistance and relapse.… read more here.

Keywords: myeloid leukemia; calcrl; drug; drug tolerant ... See more keywords
Photo from wikipedia

A multiplexable assay for screening antibiotic lethality against drug-tolerant bacteria

Sign Up to like & get
recommendations!
Published in 2019 at "Nature Methods"

DOI: 10.1038/s41592-019-0333-y

Abstract: Antibiotic screens typically rely on growth inhibition to characterize compound bioactivity—an approach that cannot be used to assess the bactericidal activity of antibiotics against bacteria in drug-tolerant states. To address this limitation, we developed a… read more here.

Keywords: tolerant bacteria; multiplexable assay; tolerant; drug tolerant ... See more keywords

Stochastic population dynamics of cancer stemness and adaptive response to therapies.

Sign Up to like & get
recommendations!
Published in 2022 at "Essays in biochemistry"

DOI: 10.1042/ebc20220038

Abstract: Intratumoral heterogeneity can exist along multiple axes: Cancer stem cells (CSCs)/non-CSCs, drug-sensitive/drug-tolerant states, and a spectrum of epithelial-hybrid-mesenchymal phenotypes. Further, these diverse cell-states can switch reversibly among one another, thereby posing a major challenge to… read more here.

Keywords: heterogeneity; cell; drug tolerant; population ... See more keywords
Photo from wikipedia

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer

Sign Up to like & get
recommendations!
Published in 2022 at "Cancer Science"

DOI: 10.1111/cas.15674

Abstract: Osimertinib is a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR‐mutated non–small‐cell lung cancer (NSCLC). However, these effects are transient and most patients develop… read more here.

Keywords: egfr mutated; resistance; drug tolerant; egfr ... See more keywords
Photo by axger from unsplash

A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum

Sign Up to like & get
recommendations!
Published in 2023 at "mBio"

DOI: 10.1128/mbio.00598-23

Abstract: M. tuberculosis (Mtb) within the caseous core of necrotic granulomas and cavities is extremely drug tolerant and presents a significant hurdle to treatment success and relapse prevention. Many in vitro models of nonreplicating persistence have… read more here.

Keywords: tuberculosis; caseum; mtb; drug tolerant ... See more keywords
Photo from wikipedia

Abstract B10: Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targted melanoma therapy

Sign Up to like & get
recommendations!
Published in 2017 at "Cancer Research"

DOI: 10.1158/1538-7445.transcontrol16-b10

Abstract: BRAFV600E mutation is observed in ~50% of melanomas. Once melanomas have progressed with acquired resistance to BRAF-targeted therapy, mutational heterogeneity presents a major challenge. While enormous effort has gone into understanding the molecular events in… read more here.

Keywords: drug; drug tolerant; tolerant cells; resistance ... See more keywords
Photo from archive.org

GPX4 Inhibition Selectively Targets Drug-Tolerant Persister Cells.

Sign Up to like & get
recommendations!
Published in 2018 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-rw2017-215

Abstract: Targeting GPX4 induces selective cell death of drug-tolerant persister tumor cells by ferroptosis. read more here.

Keywords: drug tolerant; gpx4 inhibition; tolerant persister; inhibition selectively ... See more keywords
Photo by schluditsch from unsplash

Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy

Sign Up to like & get
recommendations!
Published in 2022 at "EMBO Molecular Medicine"

DOI: 10.15252/emmm.202114903

Abstract: Entering a drug‐tolerant persister (DTP) state of cancer cells is a transient self‐adaptive mechanism by which a residual cell subpopulation accelerates tumor progression. Here, we identified the acquisition of a DTP phenotype in multidrug‐resistant (MDR)… read more here.

Keywords: drug tolerant; dtp state; tolerant persister; cancer ... See more keywords
Photo from wikipedia

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer

Sign Up to like & get
recommendations!
Published in 2018 at "Oncotarget"

DOI: 10.18632/oncotarget.25531

Abstract: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) induce a dramatic response in non–small cell lung cancer (NSCLC) patients with the ALK fusion gene. However, acquired resistance to ALK-TKIs remains an inevitable problem. In this study,… read more here.

Keywords: alk; alk positive; drug tolerant; cancer ... See more keywords
Photo from wikipedia

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier

Sign Up to like & get
recommendations!
Published in 2020 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2020.01365

Abstract: A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to… read more here.

Keywords: ada; treatment; level; drug ... See more keywords